Advertisement

Topics

FDA decision on emicizumab in hemophilia A due within five months

07:30 EDT 24 Aug 2017 | thePharmaLetter

Swiss pharma giant Roche’s regulatory application for emicizumab in hemophilia A has been given priority…

Original Article: FDA decision on emicizumab in hemophilia A due within five months

NEXT ARTICLE

More From BioPortfolio on "FDA decision on emicizumab in hemophilia A due within five months"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...